OptiNose (OPTN) shares were up more than 61% in premarket activity Thursday after the company overnight said it agreed to be acquired by Paratek Pharmaceuticals in a deal valued at up to $330 million.
The consideration payable to OptiNose shareholders is up to $14 per share, including contingent value rights tied to future commercial milestones, the companies said in a joint statement late Wednesday. It represents a 50% premium to Optinose's closing trading price on Wednesday.
The move will expand Paratek's commercial portfolio beyond its flagship antibiotic, nuzyra (omadacycline), and strengthen its focus on specialty therapies for primary care providers and specialists.
The acquisition includes OptiNose's approved product xhance (fluticasone propionate), a drug-device combination product approved to treat chronic rhinosinusitis. Paratek plans to "accelerate access for xhance beyond specialists to primary care providers maximizing the recent label expansion for CRS in a 10-million-patient market."
OptiNose also said late Wednesday it canceled its Q4 earnings conference call scheduled for March 20 following the announcement related to the takeover, which is subject to regulatory approvals.
Price: 9.71, Change: +3.71, Percent Change: +61.83
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。